Janus Henderson Global Life Sciences Fund Class A (JFNAX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.83: the stock has moved about 17% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerJanus Henderson Global Life Sciences Fund Class A (JFNAX) trades at $83.72. Janus Henderson Global Life Sciences Fund Class A (JFNAX) is a financial services company focused on long-term capital growth through investments in life science-oriented companies. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for JFNAX: JFNAX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Janus Henderson Global Life Sciences Fund Class A (JFNAX) Financial Services Profile
Janus Henderson Global Life Sciences Fund Class A (JFNAX) is a financial services firm specializing in investments within the life sciences sector, targeting long-term capital appreciation. The fund strategically allocates assets, maintaining a substantial focus on companies categorized within the life sciences, operating with a beta of 0.83.
What Is the Investment Thesis for JFNAX?
Janus Henderson Global Life Sciences Fund Class A (JFNAX) presents a focused investment opportunity within the life sciences sector. With a market capitalization of $5.60 billion, the fund is positioned to benefit from the long-term growth trends in healthcare and biotechnology. The fund's strategy of investing at least 25% of its assets in life sciences companies ensures targeted exposure to the sector. Key catalysts include ongoing advancements in medical technology and increasing demand for healthcare services driven by an aging global population. However, potential risks include regulatory changes in the healthcare industry and the inherent volatility associated with investments in biotechnology and pharmaceutical companies. The fund's beta of 0.83 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors seeking exposure to the life sciences sector.
Based on FMP financials and quantitative analysis
JFNAX Key Highlights
Market capitalization of $5.60 billion indicates a substantial presence in the asset management space.
- The fund invests at least 25% of its total assets in securities of companies categorized in the 'life sciences' sector.
- Beta of 0.83 suggests lower volatility compared to the broader market.
- The fund aims for long-term capital growth through investments in life science-oriented companies.
- No dividend yield, indicating a focus on capital appreciation rather than income generation.
Who Are JFNAX's Competitors?
JFNAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CTCAX Columbia Global Technology Growth Fund | $138.28 | +1.13% | $6.27B | — |
| CTHRX Columbia Global Technology Growth Fund Institutional 2 Class | $151.31 | +1.14% | $6.38B | — |
| JAWWX Janus Henderson Global Research Fund - T Shares | $134.37 | +0.66% | $4.77B | — |
| JDWAX Janus Henderson Global Research Fund Class A | $136.88 | +0.66% | $4.77B | — |
| JDWRX Janus Henderson Global Research Fund - R Shares | $133.90 | +0.66% | $4.77B | — |
| APO Apollo Global Management, Inc. | $114.02 | -0.28% | $65.7B | 55 5-pillar |
| ALTI AlTi Global, Inc. | $2.91 | -2.35% | $432M | — |
| GROW U.S. Global Investors, Inc. | $2.86 | -0.35% | $36.3M | 57 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JFNAX's Key Strengths?
Strong focus on the life sciences sector.
- Experienced management team.
- Diversified portfolio.
- Established brand reputation.
What Are JFNAX's Weaknesses?
Sector-specific focus may limit diversification.
- Performance is highly dependent on the life sciences sector.
- Subject to regulatory risks in the healthcare industry.
- No dividend yield may deter income-seeking investors.
What Are the Key Risks for JFNAX?
Regulatory changes in the healthcare industry could negatively impact the fund's investments.
- Economic downturns may reduce investor demand for the fund.
- Volatility in the biotechnology and pharmaceutical sectors can lead to fluctuations in the fund's performance.
- Competition from other asset management firms could reduce the fund's market share.
What Are JFNAX's Competitive Advantages?
- Established brand reputation of Janus Henderson Investors.
- Experienced portfolio management team with expertise in the life sciences sector.
- Diversified portfolio of life science companies reduces risk.
- Access to proprietary research and analysis resources.
What Does JFNAX Do?
Janus Henderson Global Life Sciences Fund Class A (JFNAX) is an investment fund managed by Janus Henderson Investors. The fund is designed to achieve long-term capital growth by investing primarily in companies operating within the life sciences sector. The fund strategically allocates its assets, with a fundamental policy to invest at least 25% of its total assets in securities of companies categorized in the 'life sciences' sector. This focus enables the fund to capitalize on the growth potential within the biotechnology, pharmaceuticals, healthcare equipment, and related industries. The fund's investment strategy involves identifying companies that the portfolio managers believe have a strong life science orientation. This includes companies engaged in research, development, production, or distribution of products and services related to healthcare, pharmaceuticals, biotechnology, and medical devices. The fund's investment decisions are based on a combination of fundamental analysis, industry research, and assessment of company-specific factors such as management quality, competitive positioning, and growth prospects. JFNAX operates within the broader asset management industry, offering investors exposure to the life sciences sector through a diversified portfolio. The fund aims to provide investors with a means to participate in the potential growth of the healthcare and biotechnology industries while mitigating risk through diversification. The fund's investment approach is designed to generate long-term returns by capitalizing on the innovation and growth within the life sciences sector.
What Products and Services Does JFNAX Offer?
- Invests primarily in securities of companies with a life science orientation.
- Aims for long-term growth of capital.
- Allocates at least 25% of total assets in companies categorized in the 'life sciences' sector.
- Focuses on companies involved in research, development, production, or distribution of healthcare-related products and services.
- Conducts fundamental analysis and industry research to identify promising investment opportunities.
- Manages a diversified portfolio of life science companies to mitigate risk.
How Does JFNAX Make Money?
- Generates revenue through management fees charged to investors.
- Fees are typically a percentage of the fund's assets under management (AUM).
- Investment decisions are made by portfolio managers based on market research and analysis.
What Industry Does JFNAX Operate In?
Janus Henderson Global Life Sciences Fund Class A (JFNAX) operates within the global asset management industry, specifically targeting the life sciences sector. The industry is characterized by increasing demand for healthcare services, driven by an aging global population and advancements in medical technology. The competitive landscape includes other asset management firms offering similar sector-specific funds, such as CTCAX, CTHRX, JAWWX, JDWAX, and JDWRX. These funds compete for investor capital by offering varying investment strategies and risk profiles within the life sciences sector.
Who Are JFNAX's Key Customers?
- Individual investors seeking exposure to the life sciences sector.
- Institutional investors, including pension funds, endowments, and foundations.
- Financial advisors who recommend the fund to their clients.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a fund, not an operating company
JFNAX Financials
Bull Case vs Bear Case
Bull Case
- Strong focus on the life sciences sector.
- Experienced management team.
- Diversified portfolio.
- Established brand reputation.
Bear Case
- Sector-specific focus may limit diversification.
- Performance is highly dependent on the life sciences sector.
- Subject to regulatory risks in the healthcare industry.
- No dividend yield may deter income-seeking investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
JFNAX Latest News
No recent news available for JFNAX.
JFNAX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for JFNAX.
Price Targets
Wall Street price target analysis for JFNAX.
JFNAX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for JFNAX; grades run from A+ (80-100) to F (below 30).
What Investors Ask About Janus Henderson Global Life Sciences Fund Class A (JFNAX) — Financials
What are the main risks for JFNAX?
The main risks for JFNAX include regulatory changes in the healthcare industry, which could impact the profitability of companies in the fund's portfolio. Economic downturns may reduce investor demand for the fund, leading to lower asset values.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.